Prelude Therapeutics Incorporated
General ticker "PRLD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $54.0M (TTM average)
Prelude Therapeutics Incorporated follows the US Stock Market performance with the rate: 39.7%.
Estimated limits based on current volatility of 8.0%: low 1.30$, high 1.52$
Factors to consider:
- Total employees count: 131 (+2.3%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operating losses, Operational and conduct risks, Funding dependency, Market competition, Product liability
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.75$, 2.58$]
- 2025-12-31 to 2026-12-31 estimated range: [0.73$, 2.34$]
Financial Metrics affecting the PRLD estimates:
- Positive: with PPE of -0.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -113.69 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 74.90 > 63.39
- Positive: Investing cash flow per share per price, % of 99.66 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
Short-term PRLD quotes
Long-term PRLD plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $7.00MM |
| Operating Expenses | $123.54MM | $132.28MM | $146.71MM |
| Operating Income | $-123.54MM | $-132.28MM | $-139.71MM |
| Non-Operating Income | $8.10MM | $10.45MM | $12.54MM |
| R&D Expense | $92.89MM | $103.39MM | $118.00MM |
| Income(Loss) | $-115.44MM | $-121.83MM | $-127.17MM |
| Profit(Loss)* | $-115.44MM | $-121.83MM | $-127.17MM |
| Stockholders Equity | $195.44MM | $237.09MM | $131.46MM |
| Assets | $220.50MM | $277.67MM | $175.51MM |
| Operating Cash Flow | $-83.73MM | $-107.06MM | $-102.89MM |
| Capital expenditure | $3.02MM | $3.51MM | $0.76MM |
| Investing Cash Flow | $81.69MM | $-34.65MM | $90.19MM |
| Financing Cash Flow | $0.81MM | $136.40MM | $-0.12MM |
| Earnings Per Share** | $-2.44 | $-2.02 | $-1.68 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.